That last paragraph in bold print sums up my previ
Post# of 15624
I'm wondering if the present management is reluctant to proceed with some of their international plans because of this pending lawsuit. Maybe this liability has them handcuffed, so-to-speak, to be more outgoing with publishing research/clinical results. Additionally, the conversion mentioned in this "Lonergan" letter resulted in a 33million share dilution which pummeled the share price at that time. Maybe a good attorney could show how this negatively affected the shareholder mentality and set up the hiring of JF which added even more disaster to OWCP momemtum. JMO.